Literature DB >> 10500060

Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.

A Attar1, B Flourié, J C Rambaud, C Franchisseur, P Ruszniewski, Y Bouhnik.   

Abstract

BACKGROUND & AIMS: No controlled trial has examined the clinical efficacy of antibiotics in small bowel bacterial overgrowth.
METHODS: Ten patients with bacterial overgrowth-related diarrhea underwent the following five 7-day treatment periods: untreated (control period), then placebo, and subsequently, in random order and blinded fashion, norfloxacin (800 mg/day), amoxicillin-clavulanic acid (1500 mg/day), and Saccharomyces boulardii (1500 mg/day). A hydrogen breath test was performed on the first and last day of each period.
RESULTS: Daily stool frequency was similar during the control and placebo periods (4.2 +/- 0.6 vs. 3.9 +/- 0.6 [mean +/- SEM], respectively). Norfloxacin and amoxicillin-clavulanic acid led to a significant reduction in daily stool frequency (2.3 +/- 0.4 and 3.0 +/- 0.5, respectively; P < 0.01 vs. placebo period) after 2.0 +/- 1.4 and 1.2 +/- 0.4 days, which was maintained for 6.1 +/- 3.7 and 6.0 +/- 9.6 days, respectively. Breath-expired H(2) volume decreased with norfloxacin (37 +/- 8 to 12 +/- 5 mL per 2 hours; P < 0.01) and amoxicillin-clavulanic acid (24 +/- 6 to 8 +/- 4 mL per 2 hours, respectively; P = 0.01), but H(2) breath test result was negative in only 3 and 5 patients.
CONCLUSIONS: Norfloxacin and amoxicillin-clavulanic acid are effective in the treatment of bacterial overgrowth-related diarrhea.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10500060     DOI: 10.1016/s0016-5085(99)70336-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  47 in total

1.  Small Intestinal Bacterial Overgrowth Syndrome.

Authors:  Jeffery S. Meyers; Eli D. Ehrenpreis; Robert M. Craig
Journal:  Curr Treat Options Gastroenterol       Date:  2001-02

2.  [Acrocyanosis: crucial symptom in a case of chronic diarrhea and weight loss].

Authors:  N Hackelsberger; T Schmidt; A Stein; W Schepp
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

3.  Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment.

Authors:  Virmeet V. Singh; Phillip P. Toskes
Journal:  Curr Treat Options Gastroenterol       Date:  2004-02

4.  Guidelines for the investigation of chronic diarrhoea, 2nd edition.

Authors:  P D Thomas; A Forbes; J Green; P Howdle; R Long; R Playford; M Sheridan; R Stevens; R Valori; J Walters; G M Addison; P Hill; G Brydon
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

5.  A 14-day elemental diet is highly effective in normalizing the lactulose breath test.

Authors:  Mark Pimentel; Tess Constantino; Yuthana Kong; Meera Bajwa; Abolghasem Rezaei; Sandy Park
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

6.  Celiac disease: management of persistent symptoms in patients on a gluten-free diet.

Authors:  David H Dewar; Suzanne C Donnelly; Simon D McLaughlin; Matthew W Johnson; H Julia Ellis; Paul J Ciclitira
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

Review 7.  A systematic review of diagnostic tests for small intestinal bacterial overgrowth.

Authors:  Reza Khoshini; Sun-Chuan Dai; Sheila Lezcano; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

8.  Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

9.  Irritable Bowel Syndrome: Bacterial Overgrowth--What's Known and What to Do.

Authors:  Mark Pimentel; Sheila Lezcano
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

10.  Consequences of Small Intestinal Bacterial Overgrowth in Obese Patients Before and After Bariatric Surgery.

Authors:  Jean-Marc Sabate; Muriel Coupaye; Séverine Ledoux; Benjamin Castel; Simon Msika; Benoit Coffin; Pauline Jouet
Journal:  Obes Surg       Date:  2017-03       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.